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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the safety and efficacy of surgery, radiotherapy, and chemotherapy as first-line treatment for people with single or multiple
brain metastases, either alone or in combination.
B A C K G R O U N D
Description of the condition
Brain metastases refer to a tumour that has spread to the brain
after originating elsewhere in the body. Brainmetastases are usually
multiple, and occur in up to 20% of people with systemic cancer
(Nayak 2012; Nussbaum 1996). The most common primary sites
are the lung and breast (Posner 1978). Prognostic factors that have
been used to stratify participants in clinical trials include: younger
age (less than 65 years), control of primary disease, absence of
systemic metastases, and good performance status (Gaspar 2000).
For many people, treatment of the brain metastasis itself is not
performed, because of the extent of the systemic disease (Kaal
2004). In people with a better prognosis, there are a variety of
treatments available to improve outcome.
Description of the intervention
Surgical resection usually involves removing a single metastasis,
under general anaesthesia. Under some circumstances, such as
some cases of cerebellar metastases, or an extensive mass, the de-
cision to operate is solely, and appropriately, guided by a patient’s
clinical condition.
Whole brain radiation therapy (WBRT) has historically been the
accepted palliative treatment of choice. It has the theoretical ad-
vantage of treating undiagnosed ’micro’ metastases, but it also irra-
diates the healthy brain, with a possible risk of impairing cognitive
function.
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Focal radiotherapy techniques, such as stereotactic radiosurgery
(SRS) or stereotactic radiotherapy (SRT), have been developed to
focus higher radiation doses on the metastases, with less damage
to the surrounding brain than WBRT. The theoretical advantage
is less cognitive impairment, but requires more intensive follow-
up, and possibly additional treatments, such as repeat SRS, or even
surgery.
Chemotherapy has typically been less frequently used as primary
therapy, but more recently, it has been given a role, mainly in
specific chemo-sensitive tumours (e.g. small cell lung cancer, lym-
phomas, and breast cancer), or when an effective chemotherapy
regime is available. The potential role of immunotherapy remains
unclear, but there are early (non-randomised) data that support the
combination of SRS and immunotherapy, although randomised
data appear to be lacking.
How the intervention might work
Interventions can be broadly classified into focal, whole brain,
and systemic therapies. Focal therapies, such as surgery or SRS,
directly treat designated brain metastasis, and are specifically de-
signed not to treat the surrounding brain prophylactically from
so-called micro-metastases, which are not present on neuro-imag-
ing (e.g. MRI). Whole brain therapies, such as WBRT, provide
coverage to the whole brain, and therefore treat the metastasis
in question and any other micro-metastases that may be present.
Systemic therapies (chemotherapy and immunotherapy) treat the
whole body, and therefore, may have an effect on the brain. Fo-
cal, whole brain, and systemic therapies are often combined, e.g.
surgery and WBRT. In general, there has been a trend to rely on
focal therapies (especially SRS), given the sensitivity of modern
neuro-imaging to detecting micro-metastases, and the desire to
avoid potential long-term neurocognitive adverse events. How-
ever, this approach can lead to greater demand for follow-up and
salvage therapy on recurrence (e.g. repeat SRS or surgery).
Details of individual interventions and how they may work are
covered in a number of single intervention Cochrane Reviews
(Fuentes 2016; Hart 2005; Patil 2012; Soon 2014; Tsao 2012).
Why it is important to do this review
Currently, there are a number of Cochrane Reviews that looked
at pairwise, independent comparisons for single or multiple brain
metastases (Fuentes 2016;Hart 2005; Patil 2012; Soon 2014; Tsao
2012). We will use these as a basis for our review, but we will
re-run the literature search and conduct our search and analysis
independently. However, using the results of the meta-analyses
in practice is difficult, because there is no resource available that
synthesises information for all comparisons. Furthermore, many
combinations of treatments have not been directly compared with
each other. Therefore, a network meta-analysis should allow a
better understanding of all available treatment options, and enable
clinicians, policymakers and carers tomore easily use this evidence.
O B J E C T I V E S
To compare the safety and efficacy of surgery, radiotherapy, and
chemotherapy as first-line treatment for people with single ormul-
tiple brain metastases, either alone or in combination.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCT) of partici-
pants with newly diagnosed metastases to the brain who were ran-
domised to treatment with any of the interventions of interest.
Types of participants
We will include adult participants (18 years and over) who are re-
ceiving an intervention of interest for newly diagnosed metastases
to the brain from any primary cancer.We will include participants
regardless of primary disease type and number of metastases. Pri-
mary disease does not need to be confirmed histologically; brain
metastases must be confirmed on neuro-imaging.
Wewill exclude trials that explored treatment for recurrent disease.
Types of interventions
Interventions of direct interest
We will include studies that evaluate one or more of the following
interventions:
• Surgical resection: all neurosurgical procedures where the
preoperative aim was to remove more tissue than was necessary
for diagnosis.
• Whole brain radiotherapy (WBRT): any dose,
fractionation, or delivery method, providing it was to the whole
brain.
• Stereotactic radiosurgery (SRS) or radiotherapy (SRT): a
localised high dose of radiation in either single or multiple
fractions; defined as 14 Gy or more in a single fraction, or 25 Gy
in five fractions, or similar doses or fractionation regimens in
between.
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• Chemotherapy: any cytotoxic agent delivered either
systemically or intrathecally, with the intention of treating the
brain metastases.
• Immunotherapy: systemically administered therapy,
designed to modulate the immune system, administered to treat
the brain metastases.
We will deal with co-interventions (e.g. SRS plus WBRT versus
surgery plusWBRT) by considering each treatment pair individu-
ally.We will also consider grouping similar treatments, in the same
way that wewill group primary treatments. Therefore, wewill con-
sider interventions individually, but will also consider combined
SRS and surgery, and combinations of different chemotherapy.
Figure 1 shows the overall network of eligible comparisons in this
review. This is based on preliminary results, and there may be
additional nodes and links that emerge during the review.
Figure 1. Preliminary network of treatment comparisons
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Inclusion of additional interventions to supplement the
analysis
If we identify any new interventions, we will consider them eligi-
ble, and include them in the network after assessing their compa-
rability with the prespecified set of competing interventions. We
will report the findings for these interventions in the results and
the conclusions of the review.
Types of outcome measures
We will estimate the relative ranking of the competing interven-
tions according to the following outcomes.
Primary outcomes
• Overall survival (OS): time from treatment to death (or
censoring) in months
Secondary outcomes
• Adverse events (AE): we will record both the nature
(defined using a standard reference terminology, e.g. MedDRA
(Medical Dictionary for Regulatory Authorities) criteria) and
timing (MeDRA 2008). We will note any further procedures
required for complications. The study report should state both
the total number of complications and complications per patient.
• Progression free survival (PFS): time from treatment to
confirmed intracranial progression. Progression should be
diagnosed using open and thorough criteria according to clinical
symptoms, imaging findings, and increased steroid use (Wen
2010).
• Quality of life (QoL): recorded using a reliable and
objective grading scale, for example the The European
Organization for Research and Treatment of Cancer (EORTC
QLQ-C30-BN20) or Functional Assessment of Cancer Therapy-
Brain (FACT-Br) (Mauer 2008).
We will present ’Summary of findings’ table(s) reporting the fol-
lowing outcomes, listed in order of priority.
• Overall survival at 3, 6, 9, and 12 months, and median
value
• Intracranial progression free survival at 3, 6, 9, and 12
months, and median value
• Change in steroid dose at three months
• Change in performance status at three months
• Grade 3 acute toxicity rate
• Grade 3 late toxicity rate
• Radionecrosis rate
Search methods for identification of studies
Trials that compare at least two of the interventions will be eli-
gible. We will search for all possible comparisons formed by the
interventions of interest.
Electronic searches
The following databases will be part of our systematic literature
search:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; latest issue) in The Cochrane Library;
• MEDLINE via Ovid (1946 to present);
• Embase via Ovid (1980 to present).
We have presented the MEDLINE Ovid search strategy in
Appendix 1. For databases other than MEDLINE, we will adapt
the search strategy accordingly.
Searching other resources
Reference search
We will search the references of included studies to identify addi-
tional studies.
Handsearch
We will handsearch the Journal of Neuro-oncology and Neuro-
oncology over the past 10 years, including related international
conference proceedings of the Society forNeuro-oncology andEu-
ropean Association for Neuro-oncology, the American Society for
Clinical Oncology, the American Society for Therapeutic Radia-
tion Oncology, and other relevant conferences that may be found
in the Journals.
Personal communication
We will contact authors of included trials and other experts in the
field by email to enquire about further potentially relevant RCTs.
Unpublished and grey literature
We will search trial registries, including clinicaltrials.gov and
isrctn.com.
Data collection and analysis
Selection of studies
We will download all titles and abstracts retrieved by elec-
tronic searching to Covidence, a reference management database
(Covidence). After de-duplication two review authors (MW and
JC) will independently assess the titles and abstracts retrieved. We
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will obtain the full-text copies of published reports for all refer-
ences assessed asmeeting the inclusion criteria. We will resolve any
disagreement through discussion, or if required, we will consult
a third person (MGH). We will identify and exclude duplicate
reports and collate multiple reports of the same study, so that each
study rather than each report is the unit of interest in the review.
Assessment of the full reports will enable the identification of
studies for inclusion in the review. Studies that are excluded at
this stage will be listed in the ’Characteristics of excluded studies’
table and we will state the reasons for exclusion.
Assessors will not be blinded to author, institution, journal of
publication or results, as the review authors are familiar with most
studies and the typographical layout of journals. However, we do
not believe this will add any selection bias, and there is equipoise
within the team as to potential benefits and harms of different
treatment options.
We will record the selection process in sufficient detail to complete
a PRISMA flow diagram.
We will retrieve articles if we feel that an article’s reference list
should be reviewed for additional relevant studies.
Data extraction and management
Two review authors (JC andMW) will independently extract data
using a standard data extraction form. Any disagreements or dis-
crepancies will be resolved by a third assessor (MGH).
Outcome data
From each included study, we will extract the outcome data pre-
viously specified:
• Time-to-event data (OS and PFS): we will extract the log
hazard ratio (HR) and its standard error (SE)
• Continuous data (QoL): we will extract the final value and
standard deviation of the outcome of interest in each treatment
arm at the end of follow-up
• Dichotomous data (AE): we will extract the number of
participants in each treatment arm who experienced the outcome
of interest, in order to estimate a risk ratio (RR).
For continuous and dichotomous data, we will extract the number
of participants assessed at endpoint.
Data on potential effect modifiers
From each included study, we will extract data on the following
study, intervention, and population characteristics that may act as
effect modifiers:
• Industry sponsorship
• Study characteristics: withdrawals, blinding, and
randomisation methods; adherence to protocol; duration of
follow-up
• Patient characteristics: age, number of metastases, primary
site, performance status (Karnofsky 1948; WHO 1982),
presence of extracranial disease, control of extracranial disease,
recursive partitioning analysis (RPA) or graded prognostic
assessment (GPA) or disease-specific GPA (ds-GPA) class,
tumour volume or diameter, Mini-mental state exam score
• Intervention details: extent of surgical resection,
radiotherapy (SRS, SRT, WBRT) dose and fractionation,
chemotherapy and immunotherapy agents and regime. For SRS
and SRT - DMax and prescription isodose.
Other data
From each included study, we will extract the following additional
information:
• Author, year of publication, and journal citation (including
language)
• Country
• Setting
• Inclusion and exclusion criteria
• Study design, methodology
• Study population
◦ Total number enrolled
◦ Patient characteristics
◦ Age
◦ Sex
◦ Comorbidities
◦ Previous treatment
Assessment of risk of bias in included studies
Two review authors (JC andMW) will apply the ’Risk of bias’ tool
independently, and resolve differences by discussion or by appeal
to a third review author (CH).
We will assess and report on the methodological risk of bias of
included studies, in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions for the following items for RCTs
(Higgins 2011).
• Selection bias: random sequence generation and allocation
concealment
• Performance bias: blinding of participants and personnel
(i.e. treatment providers)
• Detection bias: blinding of outcome assessment
• Attrition bias: incomplete outcome data
• Reporting bias: selective reporting of outcomes
• other possible sources of bias (e.g. industry funding)
We will judge each item at high, low, or unclear risk of bias, as
set out in the criteria provided by Higgins 2011, and provide a
quote from the study report, a statement to justify the judgement,
or both, for each item in the ’Risk of bias’ table. We will sum-
marise results in both a ’Risk of bias’ graph and a ’Risk of bias’
summary. When interpreting treatment effects and meta-analyses,
we will take the risk of bias for the studies that contribute to that
outcome into account. Where information on risk of bias relates
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to unpublished data or correspondence with a trialist, we will note
this in the ’Risk of bias’ table. We will assess attrition rates for each
outcome (e.g. attrition rates may be different for OS and toxicity).
For outcomes with more than 50% attrition, we will conduct a
sensitivity analysis to explore the impact of the missing data.
Measures of treatment effect
We will summarise treatment effects for binary outcomes, at fixed
time points, as odds ratios (ORs), as they are more convenient for
the network meta-analysis. We will summarise treatment effects
for time-to-event outcomes as hazard ratios (HR). In addition to
summarising the treatment effects for all pairwise comparisons,
we will summarise the uncertainty in treatment effect estimates,
in term of the probability of each treatment being ranked most-
effective, second most effective, etc.We will select appropriate dis-
tributions for other endpoints, e.g. continuous endpoints analysed
on linear scales. We will pool overall survival and intracranial pro-
gression free survival, based on rates at specified time points (3, 6,
9, and 12 months), and provide median values for both outcomes.
We will pool quality of life data by normalising each scale and then
combining the continuous values.
Unit of analysis issues
If the HR and its variance are not presented, we will attempt to
extract the data required to estimate them (Parmar 1998).
Dealing with missing data
In the case of missing data required for the review outcomes, we
will contact the study authors. Where possible, we will extract all
data for an intention to treat (ITT) analysis. We will not impute
any missing data.
Assessment of heterogeneity
We will assess the presence of clinical heterogeneity by comparing
the trial and study population characteristics across all eligible
trials. We will also assess the extent of heterogeneity with pairwise
comparisons, using the I² statistic, the Cochrane Q-Test, and by
visually inspecting forest plots.
Assessment of transitivity across treatment
comparisons
We will evaluate the underlying consistency assumption by com-
paring direct and indirect estimates of treatment effects where both
are available. We will also evaluate overall model fit, using residual
deviance.
Assessment of reporting biases
We intend to construct a funnel plot of treatment effect versus
precision within pairwise comparisons, in order to investigate the
likelihood of publication bias. If these plots suggest that treatment
effects may not be sampled from a symmetric distribution, we will
consider trim and fill analyses.
Data synthesis
Methods for direct treatment comparisons
We will perform standard pairwise meta-analyses in Review Man-
ager 5 RevMan 2014. Given the likely heterogeneity of the trials,
we will use a random-effects model. We will pool outcomes based
on overall survival, progression, and toxicities. We will pool overall
survival and intracranial progression free survival based on rates
at specified time points (3, 6, 9, and 12 months), and provide
median values for both outcomes. We will pool quality of life data
by normalising each scale and them combining the continuous
values.
Methods for indirect and mixed comparisons
Wewill performnetworkmeta-analysis usingBayesianhierarchical
models estimates, using Markov Chain Monte Carlo (MCMC)
methods, as implemented in OpenBUGS (OpenBUGS 2009).
We will report posterior means, medians, and credible intervals.
We will implement the network meta-analysis as a Bayesian hi-
erarchical model as described in Dias 2013a, Dias 2013b, and
Hawkins 2015. We will use appropriate likelihood functions for
the various data types. We will consider both random-effects and
fixed-effect models. We will estimate the model parameters, us-
ing MCMC techniques, as implemented in WinBUGS. We will
run three chains, starting from different initial values. We will use
vague priors for the treatment effects and study level intercepts
(e.g. N (0.104 for treatment effects on the log hazard or log odds
ratio scale). We will use a U (0.5) prior for the standard deviation
for the random-effects analysis of binary endpoints on the logit
scale. We will run models for sufficient iterations during the burn-
in and monitoring periods to provide adequate convergence and
precision. We will assess convergence using Brooks GelmanRubin
(BGR) plots and by examining trace plots (Brooks 1998). We will
judge the adequacy of Monte-Carlo sampling using the Rhat or
similar statistics (Brooks 1998). We will compare model fit using
the deviance information criterion (DIC (Spiegelhalter 2002)).
We will assess the validity and utility of the network meta-analysis
model by examining the consistency between direct and indirect
estimates of treatment effects, where both direct and indirect evi-
dence existed for a given treatment comparison (Dias 2013a).
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Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In standard pairwise meta-analyses, we will assume different het-
erogeneity for each pairwise comparison. In the network meta-
analysis, we will assume a common random-effects variance across
the different comparisons.
Investigation of heterogeneity and inconsistency
If sufficient studies are available, we will perform network meta-
regression, subgroup analyses, or both, by using the following ef-
fect modifiers as possible sources of inconsistency, heterogeneity,
or both:
• Primary tumour origin: specifically lymphoma, leukaemia,
small or non-small cell lung cancer
• Surgery: complete versus incomplete surgical resection
• WBRT conventional versus altered dose and fractionation
schemes
• Primary disease site (as source of metastasis)
• Age profile of participants
• Performance status
• Presence of extracranial disease
• Staging technique used to assess presence or absence of
extracranial disease
• Subsequent treatment (salvage, or follow-up treatment)
We recognise that not all studies may provide sufficient informa-
tion to allow us to include them, and conduct subgroup analyses.
Sensitivity analysis
We plan to undertake a sensitivity analysis using two scores of
methodological quality that show the greatest variation. The RCT
quality scores that we will derive will be used to identify the
strengths or weaknesses of trial designs, and will enable us to as-
sess the effect of study quality on outcomes. As part of this, we
will assess whether the results of the network meta-analysis persist
when restricted to studies with lower risk of bias.
The study group are also interested in exploring additional novel
computational methods to analyse the data. These results will lie
outside the review, but will use the same underlying data set. See
Williams 2015 as an example.
Summary of findings
We will present the overall certainty of the evidence for each out-
come (see Types of outcome measures), according to the GRADE
approach, which takes into account issues related to internal valid-
ity (risk of bias, inconsistency, imprecision, publication bias), and
also to external validity, such as directness of results (Langendam
2013). We will create a ’Summary of findings’ table, based on the
methods described the Cochrane Handbook for Systematic Reviews
of Interventions andusingGRADEproGDT (see draft inAppendix
2 (GRADEpro GDT; Higgins 2011)). We will use the GRADE
checklist and GRADE Working Group certainty of evidence def-
initions (Meader 2014). We will downgrade the evidence from
high quality by one level for serious (or by two for very serious)
concerns for each limitation:
• High-certainty: we are very confident that the true effect
lies close to that of the estimate of the effect.
• Moderate-certainty: we are moderately confident in the
effect estimate. The true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is substantially
different.
• Low-certainty: our confidence in the effect estimate is
limited. The true effect may be substantially different from the
estimate of the effect.
• Very low-certainty: we have very little confidence in the
effect estimate. The true effect is likely to be substantially
different from the estimate of effect.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Brain Neoplasms/
2. ((brain or cerebral or intracranial or intra-cranial or intracerebral or intra-cerebral or cerebellum) adj5 (metasta* or cancer* or tumor*
or tumour* or neoplas* or carcinoma* or malignan* or secondar*)).ti,ab.
3. 1 or 2
4. exp Radiotherapy/
5. radiotherapy.fs.
6. radiotherap*.ti,ab.
7. (radiat* or irradiat*).ti,ab.
8. (radiosurg* or stereota* or linear accelerator* or cyberknife or gamma-knife or gamma knife or linac*).ti,ab.
9. (whole brain radiotherapy or whole-brain radiotherapy or wbrt or WBRT).ti,ab.
10. 4 or 5 or 6 or 7 or 8 or 9
11. exp Antineoplastic Agents/
12. Antineoplastic Combined Chemotherapy Protocols/
13. chemotherap*.ti,ab.
14. drug therapy.fs.
15. exp Combined Modality Therapy/
16. 11 or 12 or 13 or 14 or 15
17. exp Neurosurgical Procedures/
18. surgery.fs.
19. (surg* or neurosurg* or neuro-surg* or neuro surg* or exis* or resect*).ti,ab.
20. 17 or 18 or 19
21. 10 or 16 or 20
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22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. randomized.ab.
25. placebo.ab.
26. clinical trials as topic.sh.
27. randomly.ab.
28. trial.ti.
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. (animals not (humans and animals)).sh.
31. 29 not 30
32. 3 and 21 and 31
Key:
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
pt = publication type
ab = abstract
sh = subject heading
ti = title
Appendix 2. Draft summary of findings table
Example summary of findings table
Title: Stereotactic radiotherapy versus stereotactic radiotherapy plus whole brain radiotherapy
Patient or population: Patients with one more newly diagnosed brain metastasis
Settings: Hospital
Intervention: Stereotactic radiotherapy
Comparison: Stereotactic radiotherapy plus whole brain radiotherapy
Outcomes Illustrative comparative risks* Relative effect
(95% CI)
No of partici-
pants
(studies)
Certainty of evi-
dence
(GRADE)
Comment
Assumed risk Corresponding
risk
1a Overall Sur-
vival at 3, 6, 9,
and 12 months
1b Overall Sur-
vival (median in
months)
2a. Intracranial
progression free
survival at 3, 6, 9,
and 12 months
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(Continued)
2b. Intracranial
progression free
survival (median
in months)
3 Change
in steroid dose at
3 months (pro-
portion of pa-
tients with sta-
ble or decreased
steroid dose)
4. Change in
performance sta-
tus at 3 months
(proportion of
patients with im-
proved or stable
performance sta-
tus by ECOG or
KPS)
5. Grade 3 acute
toxicity
rate (proportion
of patients with
grade 3 or 4 tox-
icity)
6. Grade 3 late
toxicity rate
7. Radionecrosis
rate within 12
months of treat-
ment
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio; OR: odds ratio; ECOG: Eastern Cooperative
Oncology Group; KPS: Karnofsky Performace Status
GRADE Working Group grades of evidence
High-certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate-certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low-certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
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(Continued)
change the estimate.
Very low-certainty: We are very uncertain about the estimate
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